This year has been a great year for friends struggling with obesity! Because this year saw the emergence of two remarkable weight loss medications: 1. Semaglutide injection 2. Tirzepatide.
In June of this year, the popular weight loss injection—Semaglutide—was officially approved for use in China.
In July of the same year, the national drug website revealed that Tirzepatide, which is more effective for weight loss than Semaglutide, has entered the Chinese market!
The introduction of these two scientific weight loss injections has undoubtedly shocked friends who are struggling with the unsatisfactory effects of exercise and dieting, making them eager to become clinical trial participants, even if that makes them the “guinea pig”!
What sets Tirzepatide apart is that it is the world’s leading “dual receptor agonist for incretins.” The term “dual” suggests that its weight loss potential may surpass that of Semaglutide, bringing unprecedented effective weight loss experiences to those dealing with obesity.
Based on this, many people have high hopes for Tirzepatide. Many who have tried other weight loss methods express that perhaps it—Tirzepatide—can be dubbed the “super powerful weight loss miracle.”
Talk is cheap; let’s present solid evidence for the weight loss champion: Why is Tirzepatide claimed to be the strongest for weight loss?
Semaglutide, its predecessor, has performed exceptionally well globally, especially in treating diabetes and controlling blood sugar levels. Its evident weight loss effects have benefited many, leading them to no longer rely on dieting (starvation), exercise, physiotherapy, herbal dehydration, laxatives, acupuncture, or thread embedding for weight loss. Its successful rise is attributed to its ability to significantly promote weight loss without requiring “overweight individuals” to rely too heavily on dietary control and intense exercise.
What exactly is the principle behind Semaglutide’s weight loss?
After regular use of Semaglutide for some time, a person’s appetite gradually diminishes, and the gastrointestinal process of food digestion and absorption also becomes slower. This change leads to an unintentional reduction in food intake, while this medication decreases the efficiency of food digestion, significantly enhancing the rate of visceral fat burning, and that’s how fat is gradually shed.
The source of this effect comes from a key receptor in the human body known as the “glucagon-like peptide-1 receptor.” Its widespread activation kicks off the weight loss journey. And the weight loss drug Semaglutide has successfully unlocked this weight loss code by acting as a “glucagon-like peptide-1 receptor agonist.”
However, what is less known is that there is another partner hidden in the human body that fights alongside “glucagon-like peptide-1″—the “glucose-dependent insulinotropic polypeptide.” Both belong to the “incretin” family and together regulate the body’s blood sugar and metabolic balance. Tirzepatide can simultaneously activate both the “glucagon-like peptide-1 receptor” and the “glucose-dependent insulinotropic polypeptide.”
